title: Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II.
abstract: During a general population follow-up study in Health Region I in Norway, 162 patients with multiple myeloma (MM) were diagnosed. 71 of these (44%) were asymptomatic, and were observed without chemotherapy. The great majority (90%) were in stage I, and there were only 2 with light chain disease. 45 of the 71 asymptomatic patients developed progressive disease during the 4-5 year follow-up period. Estimated median time to disease progression was 26 months. The presence at diagnosis of osteolytic lesions and/or at least 20% plasma cells in the bone marrow defined a group with significantly shorter time to progression (median 10 vs 39 months). Median survival from diagnosis for the asymptomatic patients was 45 months, which is significantly longer than the 26 months of the symptomatic group. However, when estimated from the start of treatment, the survival was similar for the two groups.
authors.affiliation: Ullevål University Hospital, Oslo, Norway.
authors.forename: F
authors.initials: F
authors.lastname: Wisløff
authors.forename: P
authors.initials: P
authors.lastname: Andersen
authors.forename: T R
authors.initials: TR
authors.lastname: Andersson
authors.forename: E
authors.initials: E
authors.lastname: Brandt
authors.forename: C
authors.initials: C
authors.lastname: Eika
authors.forename: K
authors.initials: K
authors.lastname: Fjaestad
authors.forename: T
authors.initials: T
authors.lastname: Grønvold
authors.forename: B
authors.initials: B
authors.lastname: Holm
authors.forename: K
authors.initials: K
authors.lastname: Løvåsen
authors.forename: G E
authors.initials: GE
authors.lastname: Tjønnfjord
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D009664:Norway / Q000453:epidemiology; D016019:Survival Analysis